Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
News Jun 17, 2009
Elusys Therapeutics and Lonza Sales AG entered into an agreement for the production of Anthim™, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection.
Under this agreement, Lonza will provide process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
"Elusys is pleased to initiate a partnership with Lonza for the production of Anthim. Lonza has considerable experience in large-scale manufacturing of monoclonal antibodies and a well-established reputation with regulatory agencies for the production of licensed products," commented James Porter, Vice President of Development and Manufacturing at Elusys.
"Elusys has developed a very promising antibody therapeutic and we are proud to be able to support the further development of Anthim towards its commercial use," added Dr. Stephan Kutzer, Head of Lonza Biopharmaceuticals.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.